Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2021 Dec 14;15(12):e0009993. doi: 10.1371/journal.pntd.0009993

Laboratory diagnostic, epidemiological, and clinical characteristics of human leptospirosis in Okinawa Prefecture, Japan, 2003–2020

Tetsuya Kakita 1,*, Sho Okano 1,¤a, Hisako Kyan 1, Masato Miyahira 1,¤b, Katsuya Taira 1,¤a, Emi Kitashoji 2, Nobuo Koizumi 3,*
Editor: Vasantha kumari Neela4
PMCID: PMC8670671  PMID: 34905535

Abstract

Background

Leptospirosis is considered an endemic disease among agricultural workers in Okinawa Prefecture, which is the southernmost part of Japan and has a subtropical climate, but data on the current status and trend of this disease are scarce.

Methodology/principal findings

We conducted a retrospective study of clinically suspected leptospirosis patients whose sample and information were sent to the Okinawa Prefectural Institute of Health and Environment from November 2003 to December 2020. Laboratory diagnosis was established using culture, nested polymerase chain reaction (PCR), and/or microscopic agglutination test (MAT) with blood, cerebrospinal fluid, and/or urine samples. Statistical analyses were performed to compare the epidemiological information, clinical features, and sensitivities of diagnostic methods among laboratory-confirmed cases. Serogroups and the species of Leptospira isolates were determined by MAT using 13 antisera and flaB sequencing.

A total of 531 clinically suspected patients were recruited, among whom 246 (46.3%) were laboratory confirmed to have leptospirosis. Among the confirmed cases, patients aged 20–29 years (22.4%) and male patients (85.7%) were the most common. The most common estimated sources of infection were recreation (44.5%) and labor (27.8%) in rivers. Approximately half of the isolates were of the L. interrogans serogroup Hebdomadis. The main clinical symptoms were fever (97.1%), myalgia (56.3%), and conjunctival hyperemia (52.2%). Headache occurred significantly more often in patients with Hebdomadis serogroup infections than those with other serogroup infections. The sensitivities of culture and PCR exceeded 65% during the first 6 days, while the sensitivity of MAT surpassed that of culture and PCR in the second week after onset. PCR using blood samples was a preferable method for the early diagnosis of leptospirosis.

Conclusions/significance

The results of this study will support clinicians in the diagnosis and treatment of undifferentiated febrile patients in Okinawa Prefecture as well as patients returning from Okinawa Prefecture.

Author summary

Leptospirosis is an important but largely under-recognized public health problem in the tropics. Recreational leptospirosis is a major cause of infection; people contract leptospirosis via recreational activities in rivers or lakes. Okinawa Prefecture is located in the southernmost part of Japan, has a subtropical climate, and is a major tourist destination, with an estimated 10 million visitors annually. In this study, we revealed that the trend of leptospirosis in this prefecture has changed. Leptospirosis was considered an endemic disease among agricultural workers; however, during the last 17 years, most of the confirmed cases in Okinawa Prefecture were attributable to recreation or labor in rivers in the summer in the northern part of the main island of Okinawa and the Yaeyama region, which are designated as national parks with abundant nature. Since recreation in rivers is the most popular activity among tourists in Okinawa Prefecture, leptospirosis is a health concern not only for residents of Okinawa Prefecture but also for tourists.

Introduction

Leptospirosis is the most common zoonotic disease and is caused by infection with pathogenic spirochetes of the genus Leptospira, which comprises 64 species divided into 24 serogroups and more than 300 serovars [14]. Leptospira spp. colonize the proximal renal tubules of maintenance hosts, including wild animals such as rats and wild boars, livestock such as cattle and pigs, and companion animals such as dogs and are shed in their urine [2,5,6]. Humans are percutaneously or permucosally infected with Leptospira spp. by direct contact with the urine of maintenance hosts or by indirect contact with soil or water contaminated with infected urine [3,6,7].

Approximately one million cases of human leptospirosis occur worldwide annually, along with 58,900 deaths [8]. Seventy-three percent of the world’s leptospirosis cases and deaths occur in tropical regions [8]. Human leptospirosis is characterized by a range of clinical symptoms, ranging from mild influenza-like illnesses (such as fever, myalgia, and headache) to a severe form called Weil’s disease (which presents with jaundice and acute renal failure) and leptospirosis pulmonary hemorrhage syndrome (which presents as pulmonary hemorrhage without jaundice or renal failure). The mortality rates of Weil’s disease and leptospirosis pulmonary hemorrhage syndrome are >10% and >50%, respectively [9]. Since most symptomatic patients present with a mild form of the disease, with nonspecific manifestations that are easily confused with those of other infectious diseases in the tropics, such as dengue fever, malaria, and scrub typhus, leptospirosis remains a significant diagnostic challenge for clinicians [6,10]. The incubation period for leptospirosis ranges from 3 days to 1 month, with an average of 7–12 days [6,7]. Leptospirosis can be treated with antibiotics such as doxycycline and ampicillin; thus, early treatment can reduce suffering and mortality [3,6,1113].

Definitive diagnosis of leptospirosis is based on laboratory diagnostic methods such as Leptospira culture, DNA detection via polymerase chain reaction (PCR), and antibody detection by microscopic agglutination test (MAT) using paired serum samples. Choosing adequate methods and clinical samples depends on the phase of the infection. Leptospira spp. exist in the blood of patients for approximately 10 days after disease onset (leptospiraemic phase) [14]. Leptospira spp. also appear in other body fluids, such as urine and cerebrospinal fluid (CSF), a few days after disease onset [14]. For the isolation and detection of Leptospira spp., blood is the most suitable sample in the leptospiraemic phase, while urine is the most suitable sample after approximately 1 week after disease onset (leptospiraemic phase), when anti-Leptospira antibodies are produced [14]. Anti-Leptospira antibodies can be detected by MAT in the blood approximately 5–10 days after disease onset [14].

In Japan, leptospirosis in humans has been considered a notifiable disease based on laboratory diagnosis under the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (Infectious Diseases Control Law of Japan) since November 2003. In the National Epidemiological Surveillance of Infectious Disease study, 16–76 annual cases of human leptospirosis were reported in Japan between 2004 and 2020, with an average of 32 cases per year (0.02/100,000) [15]. In Okinawa Prefecture, located in the southernmost part of Japan, which has a subtropical climate, the number of leptospirosis cases ranged from four to 43 per year (average 14.4±10.6; 1.02/100000) [16], and accounted for more than half of all cases in Japan [15]. Leptospirosis was considered an endemic disease among agricultural workers in Okinawa Prefecture; thus, an in-house leptospirosis vaccine was introduced on a remote island [17,18]. Although there are some case reports on human leptospirosis [1922], the current status and trend of this disease remain scarce in this prefecture.

The present report describes the results of a retrospective study comparing the availability of laboratory diagnostic methods for leptospirosis and also analyzing Leptospira isolates and epidemiological and clinical features of confirmed leptospirosis cases in Okinawa Prefecture during the period from November 2003 to December 2020.

Methods

Ethics statements

Ethical clearance was not required because sample collection was performed under the Infectious Diseases Control Law of Japan and was not performed specifically for the present study. The Medical Research Ethics Committee of the Okinawa Prefectural Institute of Health and Environment for the use of human subjects exempts their reviews for the characterization of Leptospira isolates obtained by laboratory diagnosis performed under the law and information that has already been anonymized and cannot identify individuals.

Surveillance, case definition, and data collection

This retrospective study involved 531 patients who were clinically diagnosed with leptospirosis by physicians at clinics and hospitals in Okinawa Prefecture. According to the National Epidemiological Surveillance of Infectious Diseases under the Infectious Diseases Control Law of Japan, clinical samples and leptospirosis surveillance data were collected, and the clinical samples were sent to the Okinawa Prefectural Institute of Health and Environment through regional public health centers for laboratory confirmation. The inclusion criterion was clinically suspected leptospirosis cases from which at least one of the clinical samples was collected, while the exclusion criterion was the cases from which no clinical samples were collected. Since at least one clinical sample was taken from all 531 suspected cases, there were no excluded cases for laboratory diagnosis. The case definition of confirmed leptospirosis is a person with clinical symptoms compatible with leptospirosis and with laboratory confirmation of acute infection (see “Laboratory diagnostics for leptospirosis”). One of the confirmed cases was imported; the patient had contracted leptospirosis in Thailand, and the case was removed from epidemiological and clinical analyses. Seven cases were not included in the sensitivity comparison of diagnostic methods because of a lack of information.

Leptospirosis surveillance data including date of onset and sample collection, patient sex and age, patient symptoms, and epidemiological data, such as estimated infection source, occupation, and estimated area of infection, were obtained from the survey form submitted by medical institutions. The duration between symptom onset and sample collection was calculated by setting the day of onset to the first day of illness. Age was used as a continuous and categorical variable with age groups: 0–9, 10–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79, and 80–89 years. The patients’ symptoms included fever, myalgia, conjunctival suffusion, arthralgia, renal dysfunction, liver dysfunction, headache, gastroenteritis, jaundice, shock, Jarisch–Herxheimer reaction, lymphadenopathy, meningitis, disturbance of consciousness, rash, upper respiratory inflammation, and lower respiratory inflammation. The estimated infection source was classified as recreation in rivers, labor in rivers, labor or recreation in freshwater other than rivers, agriculture, and direct or indirect contact with rodents. Okinawa Prefecture was divided into five regions: northern, central, and southern regions of Okinawa Main Island, the Yaeyama region (including Ishigaki Island and Iriomote Island), and the Miyako region.

Laboratory diagnostics for leptospirosis

Culturing of Leptospira spp. from blood, CSF, and urine samples was performed using liquid Ellinghausen–McCullough–Johnson–Harris (EMJH) medium and/or Korthof’s medium [7], and 50 μL of clinical sample were inoculated into 10 mL of liquid medium and incubated at 30°C for two months.

For Leptospira DNA detection, DNA was extracted from 200 μL of blood, CSF, or urine samples using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). The extracted DNA was then subjected to nested PCR targeting flaB for pathogenic Leptospira spp. [23].

To detect anti-Leptospira antibodies in paired serum samples, MAT was performed using 13 serovar strains of 12 serogroups, as previously described [23]. A positive MAT result was defined as a four-fold or greater increase in titers between acute and convalescent serum samples.

Species and serogroup identification for Leptospira isolates

To identify the serogroups of the 123 Leptospira isolates, MAT was performed using 13 antisera diluted at 1:400 to 1:102400 through two-fold serial dilutions [23].

Leptospiral DNA was extracted from 43 of the 123 isolates using the QIAamp DNA Blood Mini Kit (Qiagen) and subjected to PCR targeting flaB using the primers L-flaB-F1 and L-flaB-R1 [23]. The nucleotide sequences of the amplicons were determined using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). The flaB sequences were then deposited in a public database (DDBJ accession numbers LC642635–LC642675).

Statistical analysis

Epidemiological and clinical features were compared between confirmed and non-confirmed cases and between Hebdomadis serogroup-infected cases and other serogroup-infected cases. The sensitivity of each diagnostic method was calculated as the number of positives in each method / the number of confirmed cases. A reciprocal MAT titer of 320 was regarded as positive, irrespective of acute or convalescent samples, for the analysis of the sensitivity comparison of diagnostic methods. Continuous data were analyzed using Welch’s t-test, Student’s t-test, or Mann–​Whitney U test and categorical data using 2 × 2 Fisher’s exact test. Odds ratios (ORs) with corresponding 95% confidence intervals were calculated to evaluate the association of patients’ symptoms with each group.

Results

In the 17-year-period from November 2003 to December 2020, a total of 388 blood, 29 CSF, and 300 urine samples from 531 patients clinically suspected of leptospirosis were subjected to laboratory diagnosis (Fig 1).

Fig 1. Sample collection and the results for laboratory diagnostics.

Fig 1

The lowest boxes indicate the results of laboratory diagnostics, culture, DNA detection by flaB-nested PCR, and antibody detection by microscopic agglutination test (MAT). The numbers in the lowest boxes represent the number of positives / the number of patients tested. +; successful collection, -; unsuccessful collection, CSF; cerebrospinal fluid.

Overall, 246 (46.3%) patients were positive based on any of the three diagnostic tests for leptospirosis (Table 1). The positivity rates for culture and DNA detection were 34.8% and 34.5%, respectively, while blood samples showed the highest positivity rate in both culture (34.2%) and DNA detection (29.3%). Antibody detection using paired sera showed positivity in 49.9% (177/355) of suspected cases. All culture- and/or PCR-positive cases in the acute samples were MAT-positive in their convalescent serum samples. The diagnostic agreement between culture and nested PCR was 66%; nested PCR detected leptospiral DNA in 21 culture-negative samples, while Leptospira spp. were isolated from 12 PCR-negative cases.

Table 1. Results of laboratory diagnoses of leptospirosis among 531 patients with suspected leptospirosis in Okinawa Prefecture, 2003–2020.

Diagnostics Number of positives/number of patients tested Positivity rate (%)
Clinical sample
    Blood Culture 119/348 34.2
DNA detection 89/304 29.3
    Cerebrospinal fluid (CSF) Culture 3/21 14.3
DNA detection 1/26 3.8
Urine Culture 1/265 0.4
DNA detection 35/271 12.9
    Paired sera Antibody detection 177/355 49.9
Diagnostic method
Culture (blood, CSF, urine) 122/351 34.8
DNA detection (blood, CSF, urine) 108/313 34.5
Antibody detection (paired sera) 177/355 49.9
Culture only 18/34 52.9
DNA detection only 4/26 15.4
Antibody detection only 49/139 35.3
Culture/DNA detection 47/116 40.5
Culture/antibody detection 26/45 57.8
DNA/antibody detection 4/15 26.7
Culture/DNA detection/antibody detection 98/156 62.8
Total 246/531 46.3

Epidemiological features of the confirmed leptospirosis cases

Epidemiological information on the confirmed cases is shown in Table 2. The number of confirmed cases per month (the month of patient symptom onset) was highest in September (93 cases, 38.0%), followed by August (81 cases, 33.1%) and October (26 cases, 10.6%). Patient ages ranged from three to 84 years (median [interquartile range]: 31 [2046]), and age of 20–29 years was the most common (55 cases, 22.4%). The sex ratio was unbalanced, with 210 men (85.7%) and 35 women (14.3%). Infections in rivers due to recreational activities such as swimming, canyoning, and canoeing (109 cases, 44.5%), and labor (68 cases, 27.8%), accounted for most of the estimated source of infection, while all the other infection sources such as agriculture, recreation or labor in freshwater other than rivers, and direct or indirect contact with rodents, were less than 10%. Most of the people who contracted leptospirosis in rivers via working were leisure guides (57 cases, 83.8%). Most were infected in the Yaeyama area (120 cases, 49.0%) and the northern part of Okinawa Main Island (96 cases, 39.2%).

Table 2. Epidemiological information on cases with confirmed leptospirosis (N = 245)a.

Month Number of positives (%)
January 0 (0.0)
February 0 (0.0)
March 1 (0.4)
April 0 (0.0)
May 1 (0.4)
June 13 (5.3)
July 18 (7.3)
August 81 (33.1)
September 93 (38.0)
October 26 (10.6)
November 9 (3.7)
December 3 (1.2)
Age Number of positives (%)
0–9 13 (5.3)
10–19 40 (16.3)
20–29 55 (22.4)
30–39 50 (20.4)
40–49 37 (15.1)
50–59 27 (11.0)
60–69 14 (5.7)
70–79 4 (1.6)
80–89 5 (2.0)
Sex Number of positives (%)
Male 210 (85.7)
Female 35 (14.3)
Estimated infection source Number of positives (%)
Recreation in rivers 109 (44.5)
Labor in riversb 68 (27.8)
Agricultural work 22 (9.0)
Recreation or labor in freshwater other than riversc 18 (7.3)
Direct or indirect contact with rodentsd 6 (2.4)
Unknown 22 (9.0)
Estimated area of infection Number of positives (%)
Yaeyama region 120 (49.0)
Northern part of Okinawa Main Island 96 (39.2)
Central part of Okinawa Main Island 9 (3.7)
Southern part of Okinawa Main Island 3 (1.2)
Miyako region 0 (0.0)
Unknown 17 (6.9)

a One of the confirmed cases was imported; the patient had contracted leptospirosis in Thailand; thus, the case was not included.

b Leisure guide, 57; civil engineering worker, 5; researcher, 3; fisherman, 1; unknown, 2.

c Civil engineering worker, 6; sanitation worker, 6; researcher, 1; unknown, 5.

d Sanitation worker in places inhabited by rats, 1; rat exterminator, 1; worker in a vegetable collection place inhabited by rats, 1; unknown, 3.

Characterization of Leptospira isolates and infecting Leptospira serogroups deduced by MAT

One hundred twenty-three Leptospira isolates were obtained in this study. The serogroups of all Leptospira isolates were identified, among which the predominant serogroups were Hebdomadis (65, 52.8%), followed by Pyrogenes (19, 15.4%) and Grippotyphosa (10, 8.1%) (Table 3).

Table 3. Serogroups of Leptospira isolates (N = 123) and infecting serogroups identified by microscopic agglutination test (MAT) in paired serum samples (N = 176) a.

Serogroup Number of positives (%)
Isolates Hebdomadis 65 (52.8)
Pyrogenes 19 (15.4)
Grippotyphosa 10 (8.1)
Autumnalis 8 (6.5)
Australis 7 (5.7)
Icterohaemorrhagiae 3 (2.4)
Javanica 3 (2.4)
Sejroe 2 (1.6)
Unidentifiedb 6 (4.9)
MAT Hebdomadis 101 (57.4)
Autumnalis 15 (8.5)
Pyrogenes 14 (8.0)
Grippotyphosa 9 (5.1)
Javanica 6 (3.4)
Australis 4 (2.3)
Ballum 3 (1.7)
Sejroe 2 (1.1)
Icterohaemorrhagiae 1 (0.6)
Multiple serogroups 21 (11.9)

a One of the confirmed cases diagnosed using MAT was imported; the patient had contracted leptospirosis in Thailand; thus, the result was not included.

b The serogroups of six isolates could not be determined due to reaction with multiple antisera.

The species of 43 Leptospira isolates were identified and, combined with the serological results, were classified as L. interrogans serogroup Hebdomadis (20, 46.5%), L. interrogans serogroup Autumnalis (6, 14.0%), L. interrogans serogroup Pyrogenes (6, 14.0%), L. borgpetersenii serogroup Javanica (2, 4.7%), L. interrogans serogroup Grippotyphosa (2, 4.7%), L. interrogans serogroup Icterohaemorrhagiae (2, 4.7%), L. interrogans serogroup Sejroe (2, 4.7%) [19], L. interrogans serogroup Australis (1, 2.3%), and L. interrogans unidentified serogroups (2, 4.7%).

The infecting serogroup was also deduced by MAT using paired serum samples, and as with the isolates, the predominant serogroup was Hebdomadis (101, 57.4%) (Table 3).

Clinical features of the confirmed leptospirosis patients

The symptoms of patients with leptospirosis are shown in Table 4. The main clinical symptoms were fever (39.3 ± 0.9°C, 97.1%), myalgia (56.3%), conjunctival hyperemia (52.2%), arthralgia (46.1%), and renal dysfunction (40.4%), and the occurrence of these symptoms was significantly higher in patients with confirmed leptospirosis than in those without leptospirosis. As more than half of the patients were infected with the serogroup Hebdomadis strains, the clinical symptoms of patients infected with serogroup Hebdomadis and other serogroup strains were compared. Only the occurrence of headaches was significantly higher in patients infected with the serogroup Hebdomadis. Furthermore, only one death (0.4%) was recorded in 2006 because of infection with the Australis serogroup.

Table 4. Clinical features of patients with leptospirosis and comparisons of clinical features in patients with leptospirosis infected with serogroup Hebdomadis and other serogroupsa.

Symptom Total patients (N = 530) Laboratory-confirmed patients (N = 245) Laboratory-unconfirmed patients (N = 285) Odds ratio [95% CI] Hebdomadis (N = 129) Others (N = 97) Odds ratio [95% CI]
Number of positives Positivity rate (%) Number of positives Positivity rate (%) Number of positives Positivity rate (%) Number of positives Positivity rate (%) Number of positives Positivity rate (%)
Fever 475 89.6 238 97.1 237 83.2 6.9 [3.1–15.5] 127 98.4 93 95.9 2.7 [0.5–15.2]
Myalgia 232 43.8 138 56.3 94 33.0 2.6 [1.8–3.7] 68 52.7 62 63.9 0.6 [0.4–1.1]
Conjunctival suffusion 189 35.7 128 52.2 61 21.4 4.0 [2.8–5.9] 66 51.2 54 55.7 0.8 [0.5–1.4]
Arthralgia 183 34.5 113 46.1 70 24.6 2.6 [1.8–3.8] 56 43.4 50 51.5 0.7 [0.4–1.2]
Renal dysfunction 158 29.8 99 40.4 59 20.7 2.6 [1.8–3.8] 44 34.1 44 45.4 0.6 [0.4–1.1]
Liver dysfunction 192 36.2 88 35.9 104 36.5 1.0 [0.7–1.4] 39 30.2 41 42.3 0.6 [0.3–1.0]
Headache 136 25.7 73 29.8 63 22.1 1.5 [1.0–2.2] 45 34.9 20 20.6 2.1 [1.1–3.8]
Gastroenteritis 131 24.7 68 27.8 63 22.1 1.4 [0.9–2.0] 34 26.4 30 30.9 0.8 [0.4–1.4]
Jaundice 89 16.8 46 18.8 43 15.1 1.3 [0.8–2.1] 22 17.1 20 20.6 0.8 [0.4–1.6]
Shock 62 11.7 36 14.7 26 9.1 1.7 [1.0–2.9] 17 13.2 16 16.5 0.8 [0.4–1.6]
Upper respiratory inflammation 44 8.3 22 9.0 22 7.7 1.2 [0.6–2.2] 11 8.5 7 7.2 1.2 [0.4–3.2]
Jarisch-Herxheimer reaction 18 3.4 16 6.5 2 0.7 1.0 [0.5–1.9] 11 8.5 5 5.2 1.7 [0.6–5.1]
Lymphadenopathy 47 8.9 15 6.1 32 11.2 0.5 [0.3–1.0] 9 7.0 5 5.2 1.4 [0.4–4.3]
Meningitis 33 6.2 14 5.7 19 6.7 0.9 [0.4–1.7] 8 6.2 5 5.2 1.2 [0.4–3.8]
Disturbance of consciousness 28 5.3 13 5.3 15 5.3 1.0 [0.5–2.2] 6 4.7 4 4.1 1.1 [0.3–4.1]
Rash 48 9.1 7 2.9 41 14.4 0.2 [0.1–0.4] 5 3.9 1 1.0 3.9 [0.4–33.7]
Lower respiratory inflammation 13 2.5 4 1.6 9 3.2 0.5 [0.2–1.7] 3 2.3 1 1.0 2.3 [0.2–22.3]

a One of the confirmed cases was imported; the patient had contracted leptospirosis in Thailand; thus, the case was not included.

Comparison of sensitivity of laboratory diagnostic methods

The sensitivity of each diagnostic method varied depending on the duration of illness (Fig 2). During days 0–6 after onset, the sensitivities of culture and DNA detection were above 65%, while the sensitivity of antibody detection exceeded that of culture and DNA detection at one week after onset.

Fig 2. Comparisons of the sensitivity of diagnostic methods on day of illness among laboratory-confirmed cases (N = 238).

Fig 2

Each plot indicates the number of positives / the number of samples tested. The reciprocal MAT titer 320 was regarded as positive, irrespective of acute or convalescent samples in this figure. Seven cases were not included in this analysis because of lack of information. The PCR-positive case on day 14 was a patient with diabetes. The vertical bars indicate the 95% confidence intervals.

Compared to PCR-negative (but antibody-positive convalescent serum sample) cases, the duration between onset and sample collection in PCR-positive cases was shorter (median [interquartile range]: 5 [3–7] days vs. 3 [2–5] days, p < 0.01) (Fig 3). The duration between symptom onset and sample collection in blood-positive/urine-negative PCR cases was shorter than that in the blood-negative/urine-positive PCR cases (3 [2–4] days vs. 4 [3–6] days, p < 0.01) (Fig 4). As with PCR, the duration between symptom onset and sample collection in culture-positive cases was shorter than that in negative cases (3 [2–5] days vs. 4 [2–6] days, p < 0.05).

Fig 3. Distributions of PCR-positivity among blood, cerebrospinal fluid (CSF), and urine (N = 125).

Fig 3

The PCR-positive results in blood and urine samples on day 14 were detected from a single patient with diabetes.

Fig 4. Distributions of the results of flaB-nested PCR in blood and urine samples from single patients (N = 96).

Fig 4

The PCR-positive case on day 14 was a patient with diabetes.

Discussion

Laboratory diagnosis is indispensable, as clinical diagnosis of human leptospirosis is difficult due to a wide variety of non-specific clinical manifestations. Moreover, for accurate laboratory diagnosis, it is important to select appropriate diagnostic methods and clinical samples according to the infection phase. The findings of the current study support those of previous studies showing that PCR using blood is a preferable method for early diagnosis of leptospirosis, while the sensitivity of MAT surpassed that of PCR and culture in the second week after onset [14,24]. Previous studies have shown that the sensitivity of conventional PCR and real-time PCR using samples in the acute phase was 60%–100%, similar to that observed in the present study [24]. However, in this study, the diagnostic agreement between PCR and culture was 66%, and there were 12 PCR-negative/culture-positive cases. Samples in which PCR-negative/culture-positive results were obtained were all blood samples. Theoretically, blood culture can detect as little as one Leptospira cell; thus, the number of Leptospira spp. may be below the limit of detection for PCR in the early acute phase. To improve the sensitivity of PCR, RNA-based (reverse transcription) PCR has been employed, which demonstrated significantly higher sensitivity than DNA-based real-time PCR using clinical samples [25,26]. In addition, Leptospira DNA was detected only in urine in some cases, even in the first week after onset (Fig 4), indicating that both blood and urine should be used for PCR even in the early phase of infection.

The prevalence of Leptospira serogroups varies depending on the maintenance hosts, environmental conditions, and infection opportunities in specific geographic regions [11,13,2733]. In the present study, approximately half of the causative Leptospira serogroups identified by culture and MAT using paired serum samples were Hebdomadis. Although serogroup Hebdomadis belongs to L. alexanderi, L. borgpetersenii, L. interrogans, L. kirschneri, L. santarosai, and L. weilii [3], all serogroup Hebdomadis isolates in Okinawa Prefecture were classified as L. interrogans; however, we did not identify the species of all isolates. Globally, the prevalence of serogroup Hebdomadis is not very high, accounting for 12% of serogroups detected in Japan other than Okinawa Prefecture [34], and 0–3.6% in other countries [32,33,3537].

The clinical symptoms of patients infected with serogroup Hebdomadis were comparable with those reported previously [6,1113,2729,32,3842] and did not differ significantly from those infected with other serogroups in this study except for headache, which was significantly higher in Hebdomadis-infected patients (Table 4). In previous case reports, four of four (100%) and three of four (75%) confirmed cases infected with serogroup Hebdomadis developed headache, while two out of four developed meningitis [43,44]. These findings suggest that serogroup Hebdomadis strains are more likely to cause headaches. The reported mortality rate of leptospirosis was 0–15.4% [8,1113,27,29,30,32,33,38,39,42], compared to 0.4% in the present study due to infection with serogroup Australis. The serogroup Hebdomadis strain exhibited no lethality (low virulence) in the hamster model of leptospirosis [45,46], which may lead to a low mortality rate.

This study revealed that most leptospirosis patients were infected in rivers in the northern part of Okinawa Main Island and Yaeyama region. The sources of infection for leptospirosis vary widely depending on the country’s industry, environment, and economic development, such as outdoor activities in rivers (freshwater swimming, canyoning, and fishing), contact with rodents, livestock (animal husbandry and slaughter), stagnant water outside rivers, and agriculture [12,27,29,3133,36,41,47]. The northern part of the main island of Okinawa and Yaeyama are rural, abundant in nature, and are designated as national parks. Outdoor activities in rivers, such as swimming, canoeing, trekking, and canyoning, are popular among both tourists and local residents. These are considered sources of infection in these areas. Although leptospirosis was not a notifiable disease before November 2003, to our knowledge, the source of leptospirosis infection in Okinawa Prefecture was 43.2% for recreation or labor in rivers and 21.0% for agricultural work from September 1988 to October 2003 (S1 Table) [48].

The number of tourists in Okinawa has been increasing and was estimated to be approximately 10 million in 2018, compared to approximately 2 million in 1988 [49]. Compared to the number before 2003, the number of patients infected in rivers increased, while the number of patients infected via agricultural work decreased. The elevation of cases was attributed to the increased numbers of tourists and their guides participating in canoeing and canyoning following the promotion of tourism in the summer months. This resulted in many confirmed cases among leisure guides, who accounted for a high proportion of the labor performed in rivers (Table 2). In addition, the proportion of males aged 20–29 years was the highest among the confirmed cases, which is attributable to the fact that the median age of the patients who contracted leptospirosis in rivers due to recreation or labor activities was 28 years, while that of patients with other infection sources was 43.5–59 years (S2 Table). The average age of patients with leptospirosis worldwide is 26.7–45 years, with individuals aged 20–29 years at high risk [8,1113,2733,38,4042,47]. In addition, males comprise 61.4–92.3% of patients with leptospirosis [8,12,13,2733,38,40,41,47]. The sex ratio of patients in the present study was comparable (83.1% to 94.4% in males) among the estimated infection sources in this study (S2 Table). These findings indicate that young people have more opportunities for infection, such as outdoor activities and occupations in rivers, but that sex imbalance was not associated with the infection sources.

In conclusion, analysis of the characteristics of human leptospirosis in Okinawa Prefecture showed that many adult males are infected with Leptospira spp. during recreation and labor in rivers in the summer in the northern part of the main island of Okinawa and the Yaeyama region; among them, the predominant infecting serogroup is Hebdomadis. Okinawa Prefecture is a major tourist destination, with an estimated 10 million visitors annually, including 7 million visitors from mainland Japan and 3 million from overseas. The median duration of stay for tourists is approximately 4 days [49]. Since the incubation period of leptospirosis is 7–12 days [7], most infected tourists develop the disease after they return home. In fact, leptospirosis patients who stayed and took part in water activities in a river of Okinawa Prefecture have been reported in prefectures other than Okinawa annually; however, this number is lower than the number of leisure guide patients [50,51], suggesting that many cases are overlooked in prefectures other than Okinawa and likely overseas. Since leptospirosis has nonspecific and variable manifestations, it is important for clinicians to extract the epidemiological features shown in this study and include leptospirosis in the differential diagnosis of all patients with undifferentiated febrile illness.

Supporting information

S1 Table. Estimated infection source of leptospirosis patients from September 1988 to October 2003 (N = 81).

(DOCX)

S2 Table. Comparisons of age and sex ratio of patients by estimated infection source (N = 245).

(DOCX)

Acknowledgments

We thank the staff of regional public health centers for collecting the clinical specimens.

Data Availability

All flaB sequences are available from the DDBJ database (accession numbers LC642635–LC642675). All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by the Japan Agency for Medical Research and Development (funding acquisition: NK; grant number: JP21fk0108139; URL: https://www.amed.go.jp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Cerqueira GM, Picardeau M. A century of Leptospira strain typing. Infect Gen Evol. 2009;9: 760–768. doi: 10.1016/j.meegid.2009.06.009 [DOI] [PubMed] [Google Scholar]
  • 2.Guglielmini J, Bourhy P, Schiettekatte O, Zinini F, Brisse S, Picardeau M. Genus-wide Leptospira core genome multilocus sequence typing for strain taxonomy and global surveillance. PLoS Negl Trop Dis. 2019;13: e0007374. doi: 10.1371/journal.pntd.0007374 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14: 296–326. doi: 10.1128/CMR.14.2.296-326.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Vincent AT, Schiettekatte O, Goarant C, Neela VK, Bernet E, Thibeaux R, et al. Revisiting the taxonomy and evolution of pathogenicity of the genus Leptospira through the prism of genomics. PLoS Negl Trop Dis. 2019;13: e0007270. doi: 10.1371/journal.pntd.0007270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ellis WA. Animal leptospirosis. In: Adler B, editor. Leptospira and Leptospirosis. Berlin: Springer; 2015. pp. 99–137. [Google Scholar]
  • 6.Haake DA, Levett PN. Leptospirosis in humans. In: Adler B, editor. Leptospira and Leptospirosis. Berlin: Springer; 2015. pp. 65–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd Edition. Melbourne: MediSci; 1999. [Google Scholar]
  • 8.Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9: e0003898. doi: 10.1371/journal.pntd.0003898 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.McBride AJA, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005;18: 376–386. doi: 10.1097/01.qco.0000178824.05715.2c [DOI] [PubMed] [Google Scholar]
  • 10.Mehta V, Bhasi A, Panda PK, Gupta P. A coinfection of severe leptospirosis and scrub typhus in Indian Himalayas. J Family Med Prim Care. 2019;8: 3416–3418. doi: 10.4103/jfmpc.jfmpc_614_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Herrmann-Storck C, Saint Louis M, Foucand T, Lamaury I, Deloumeaux J, Baranton G, et al. Severe leptospirosis in hospitalized patients, Guadeloupe. Emerg Infect Dis. 2010;16: 331–334. doi: 10.3201/eid1602.090139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Katz AR, Ansdell VE, Effler PV, Middleton CR, Sasaki DM. Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii 1974–1998. Clin Infect Dis. 2001;33: 1834–1841. doi: 10.1086/324084 [DOI] [PubMed] [Google Scholar]
  • 13.Tubiana S, Mikulski M, Becam J, Lacassin F, Lefèvre P, Gourinat AC, et al. Risk factors and predictors of severe leptospirosis in New Caledonia. PLoS Negl Trop Dis. 2013;7: e1991. doi: 10.1371/journal.pntd.0001991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. Geneva: WHO; 2003. [Google Scholar]
  • 15.National Institute of Infectious Diseases. Infectious Diseases Weekly Reports JAPAN. 2021 [cited 12 July 2021]. Available from: https://www.niid.go.jp/niid/ja/idwr.html
  • 16.Okinawa Prefectural Government. Okinawa infectious disease surveillance center. 2021 [cited 12 July 2021]. Available from: https://www.pref.okinawa.jp/site/hoken/eiken/kikaku/kansenjouhou/home.html#syugepou
  • 17.Fukumura K. Epidemiological studies on the leptospirosis in Okinawa, Part 1: prevalence of the leptospirosis in Izena Island and the prevention by vaccination. Yamaguchi Igaku 1984;33: 257–268. [Google Scholar]
  • 18.Fukumura K. Epidemiological studies on the leptospirosis in Okinawa, Part 2: serological studies on the leptospirosis and leptospirae in Okinawa Island. Yamaguchi Igaku 1984;33: 269–277. [Google Scholar]
  • 19.Kakita T, Kyan H, Miyahira M, Takara T, Nakama E, Kuba Y, et al. Novel genotypes of Leptospira interrogans serogroup Sejroe isolated from human patients in Okinawa Prefecture, Japan. J Med Microbiol. 2020;69: 587–590. doi: 10.1099/jmm.0.001169 [DOI] [PubMed] [Google Scholar]
  • 20.Nakamura M, Taira K, Itokazu K, Kudaka J, Asato R, Kise T, et al. Sporadic cases and an outbreak of leptospirosis probably associated with recreational activities in rivers in the northern part of Okinawa Main Island. J Vet Med Sci. 2006;68: 83–85. doi: 10.1292/jvms.68.83 [DOI] [PubMed] [Google Scholar]
  • 21.Narita M, Fujitani S, Haake DA, Paterson DL. Leptospirosis after recreational exposure to water in the Yaeyama islands, Japan. Am J Trop Med Hyg. 2005;73: 652–656. doi: 10.4269/ajtmh.2005.73.652 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tomari K, Toyokawa T, Takahashi T, Kakita T, Okano S, Kyan H, et al. Childhood leptospirosis in an industrialized country: Population-based study in Okinawa, Japan. PLoS Negl Trop Dis. 2018;12: e0006294. doi: 10.1371/journal.pntd.0006294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kakita T, Kuba Y, Kyan H, Okano S, Morita M, Koizumi N. Molecular and serological epidemiology of Leptospira infection in cats in Okinawa Island, Japan. Sci Rep. 2021;11: 1–8. doi: 10.1038/s41598-020-79139-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Picardeau M, Bertherat E, Jancloes M, Skouloudis AN, Durski K, Hartskeerl RA. Rapid tests for diagnosis of leptospirosis: current tools and emerging technologies. Diagn Microbiol Infect Dis. 2014;78: 1–8. doi: 10.1016/j.diagmicrobio.2013.09.012 [DOI] [PubMed] [Google Scholar]
  • 25.Backstedt BT, Buyuktanir O, Lindow J, Wunder EA, Reis MG, Usmani-Brown S, et al. Efficient detection of pathogenic leptospires using 16S ribosomal RNA. PLoS ONE. 2015;10: e0128913. doi: 10.1371/journal.pone.0128913 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Woods K, Nic-Fhogartaigh C, Arnold C, Boutthasavong L, Phuklia W, Lim C, et al. A comparison of two molecular methods for diagnosing leptospirosis from three different sample types in patients presenting with fever in Laos. Clin Microbiol Infect. 2018;24: 1017.e1–1017.e7. doi: 10.1016/j.cmi.2017.10.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Daher EF, Lima RSA, Silva Júnior GB, Silva EC, Karbage NNN, Kataoka RS, et al. Clinical presentation of leptospirosis: a retrospective study of 201 patients in a metropolitan city of Brazil. Braz J Infect Dis. 2010;14: 3–10. doi: 10.1016/S1413-8670(10)70002-7 [DOI] [PubMed] [Google Scholar]
  • 28.Goris MGA, Kikken V, Straetemans M, Alba S, Goeijenbier M, van Gorp ECM, et al. Towards the burden of human leptospirosis: duration of acute illness and occurrence of post-leptospirosis symptoms of patients in the Netherlands. PLoS ONE. 2013;8: e76549. doi: 10.1371/journal.pone.0076549 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Jauréfuiberry S, Roussel M, Brinchault-Rabin G, Gacouin A, Le Meur A, Arvieux C, et al. Clinical presentation of leptospirosis: a retrospective study of 34 patients admitted to a single institution in metropolitan France. Clin Microbiol Infect 2005;11: 391–394. doi: 10.1111/j.1469-0691.2005.01148.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Klement-Frutos E, Tarantola A, Gourinat AC, Floury L, Goarant C. Age-specific epidemiology of human leptospirosis in New Caledonia, 2006–2016. PLoS ONE. 2020;15: e0242886. doi: 10.1371/journal.pone.0242886 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Thornley CN, Baker MG, Weinstein P. Changing epidemiology of human leptospirosis in New Zealand. Epidemiol Infect. 2002;128: 29–36. doi: 10.1017/s0950268801006392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tique V, Mattar S, Miranda J, Oviedo M, Noda A, Montes E, et al. Clinical and epidemiological status of leptospirosis in a tropical Caribbean area of Colombia. BioMed Res Int. 2018;2018: 6473851. doi: 10.1155/2018/6473851 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Turnier P Le, Mosnier E, Schaub R, Bourhy P, Jolivet A, Cropet C, et al. Epidemiology of human leptospirosis in French Guiana (2007–2014): a retrospective study. Am J Trop Med Hyg. 2018;99: 590–596. doi: 10.4269/ajtmh.17-0734 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare. Leptospirosis in Japan. Infect Agents Surveil Rep. 2016;37: 103–105. [Google Scholar]
  • 35.Koizumi N, Gamage CD, Muto M, Kularatne SAM, Budagoda SBDS, Rajapakse JRPV, et al. Serological and genetic analysis of leptospirosis in patients with acute febrile illness in Kandy, Sri Lanka. Jpn J Infect Dis. 2009;62: 474–475. doi: 10.1186/1471-2334-9-48.7 [DOI] [PubMed] [Google Scholar]
  • 36.Lau CL, Watson CH, Lowry JH, David MC, Craig SB, Wynwood SJ, et al. Human leptospirosis infection in Fiji: an eco-epidemiological approach to identifying risk factors and environmental drivers for transmission. PLoS Negl Trop Dis. 2016;10: e0004405. doi: 10.1371/journal.pntd.0004405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mgode GF, Japhary MM, Mhamphi GG, Kiwelu I, Athaide I, Machang’u RS. Leptospirosis in sugarcane plantation and fishing communities in Kagera northwestern Tanzania. PLoS Negl Trop Dis. 2019;13: e0007225. doi: 10.1371/journal.pntd.0007225 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Adiga DSA, Mittal S, Venugopal H, Mittal S. Serial changes in complete blood counts in patients with leptospirosis: our experience. J Clin Diagn Res. 2017;11: EC21–24. doi: 10.7860/JCDR/2017/25706.9836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Biscornet L, de Comarmond J, Bibi J, Mavingui P, Dellagi K, Tortosa P, et al. An observational study of human leptospirosis in Seychelles. Am J Trop Med Hyg. 2020;103: 999–1008. doi: 10.4269/ajtmh.19-0228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Holla R, Darshan B, Pandey L, Unnikrishnan B, Kumar N, Thapar R, et al. Leptospirosis in coastal south India: a facility based study. BioMed Res Int. 2018;2018: 1759125. doi: 10.1155/2018/1759125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Philip N, Affendy NB, Ramli SNA, Arif M, Raja P, Nagandran E, et al. Leptospira interrogans and Leptospira kirschneri are the dominant Leptospira species causing human leptospirosis in Central Malaysia. PLoS Negl Trop Dis. 2020;14: e0008197. doi: 10.1371/journal.pntd.0008197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Rajapakse S, Weeratunga P, Niloofa R, Fernando N, de Silva NL, Rodrigo C, et al. A diagnostic scoring model for leptospirosis in resource limited settings. PLoS Negl Trop Dis. 2016;10: e0004513. doi: 10.1371/journal.pntd.0004513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Crawford SM, Miles DW. Leptospira hebdomadis associated with an outbreak of illness in workers on a farm in North Yorkshire. Br J Ind Med. 1980;37: 397–398. doi: 10.1136/oem.37.4.397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Sakula A, Moore W. Benign Leptospirosis: first reported outbreak in British Isles due to strains belonging to the Hebdomadis serogroup of Leptospira interrogans. Br Med J. 1969;1: 226–228. doi: 10.1136/bmj.1.5638.226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Fujita R, Koizumi N, Sugiyama H, Tomizawa R, Sato R, Ohnishi M. Comparison of bacterial burden and cytokine gene expression in golden hamsters in early phase of infection with two different strains of Leptospira interrogans. PLoS ONE. 2015;10: e0132694. doi: 10.1371/journal.pone.0132694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Tomizawa R, Sugiyama H, Sato R, Ohnishi M, Koizumi N. Male-specific pulmonary hemorrhage and cytokine gene expression in golden hamster in early-phase Leptospira interrogans serovar Hebdomadis infection. Microb Pathog. 2017;111: 33–40. doi: 10.1016/j.micpath.2017.08.016 [DOI] [PubMed] [Google Scholar]
  • 47.Kamath R, Swain S, Pattanshetty S, Nair NS. Studying risk factors associated with human leptospirosis. J Glob Infect Dis. 2014;6: 3–9. doi: 10.4103/0974-777X.127941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Okano S, Taira K, Nakamura M, Oshiro N, Ono A, Yonahara Y, et al. Human leptospirosis in Okinawa Prefecture, 1998–2007. Infect Agents Surveil Rep. 2008;29: 10–12. [Google Scholar]
  • 49.Okinawa Prefectural Government. Tourism directory. 2018 [cited 12 July 2021]. Available from: https://www.pref.okinawa.lg.jp/site/bunka-sports/kankoseisaku/kikaku/report/youran/h30kankoyoran.html
  • 50.Mizuno Y, Sato F, Sakamoto M, Yoshikawa K, Yoshida M, Shiba K, et al. A diagnosed case of leptospirosis by antibody tests with paired sera. Kansenshogaku Zasshi 2004;78: 288–289. doi: 10.11150/kansenshogakuzasshi1970.78.288 [DOI] [PubMed] [Google Scholar]
  • 51.Okano S, Arakaki E, Takara T, Kato T, Nidaira M, Kyan H, et al. Human leptospirosis in Iriomote Island, Okinawa Prefecture, 2013. Infect Agents Surveil Rep. 2014;35: 14–15. [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009993.r001

Decision Letter 0

Vasantha kumari Neela, Armanda Bastos

25 Sep 2021

Dear Dr. Tetsuya Kakita,

Thank you very much for submitting your manuscript "Laboratory diagnostic, epidemiological, and clinical characteristics of human leptospirosis in Okinawa Prefecture, Japan, 2003–2020" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Vasantha kumari Neela

Associate Editor

PLOS Neglected Tropical Diseases

Armanda Bastos

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: Culture, nested polymerase chain reaction (PCR), and microscopic agglutination test (MAT) were used in this study.

Reviewer #2: At the end of the introduction it is required to specify the month of the end of the period.

The objectives of the study are clearly articulated with a clear testable hypothesis stated.

The study design is appropriated to address the stated objectives.

The sample size is sufficient to ensure adequate power to address the hypothesis being tested.

The statistical analysis used to support conclusions is correct.

There are not concerns about ethical or regulatory requirements

Reviewer #3: The study by Kakita and collaborators describe a case series of Leptospirosis in Okinawa. It is a retrospective study that describes the epidemiology of human leptospirosis in in that region during 2003-2020. This case series is an interesting compilation of clinically diagnosed Leptospirosis patients, their diagnostic laboratory results, and their epidemiological risk factors.

Although the data is present in the manuscript, the analysis would benefit from a better description of the study population, surveillance and case definitions including inclusion/exclusion criteria, and a flow chart describing the results on the tests performed (partially described in figure 1). The authors include a STROBE checklist, but this study is a case series, therefore the criteria for a cross sectional study are not applicable. I recommend rewriting the abstract accordingly, and reorganising the methods and results sections to resemble more appropriately a case series (as reference case report studies, please see Ko et al 1999 Lancet, Ciceron et al 2000 Eur J Epidemiol, Galan et al 2021 PLoS One).

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: This is a straight forward epidemiologic study with clear presentation

Reviewer #2: The analysis is presented match the analysis plan.

The results are clearly and completely presented.

In Table 3. Epidemiological information on cases with confirmed leptospirosis

The column headings are offset

S1 Table. Comparisons of age and sex ratio of patients by estimated infection source.

Percentages of estimated infection source of missing male patients

Reviewer #3: The analysis is appropriate for the retrospective case report design. Figure one can include more detail about the tests performed and excluded cases.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The conclusion is reasonable.

Reviewer #2: The conclusions are supported by the data presented.

Reviewer #3: The conclusions are supported, Leptospirosis should be suspected in a febrile subject and the appropriate diagnostic workup should be adjusted by days of illness to maximise the sensitivity of the available tests.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: a minor typo needed be fixed.

Line 375: was to were

Line 360: are to is.

Line 361: canyoning,

Line 384: that --> those

Reviewer #2: (No Response)

Reviewer #3: (No Response)

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: Reasonable.

Reviewer #2: The manuscript reports the laboratory, clinical, and epidemiological characteristics of human leptospirosis from 18-year-old samples in Japan. Analysis and results of laboratory samples are important to characterize the behavior of Leptospirosis in Okinawa Prefecture.

The month of the end of the study period remains to be specified.

Reviewer #3: The study is quite informative and of clinical and epidemiological value. It summarises over a decade of experience on an important endemic zoonotic disease in the described region. it also serves to monitor future dynamics of serovars, test performance, and changes in clinical presentations or risk factors for acquiring the infection. These findings can help inform local public health policies.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Christian A Ganoza, MD.

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009993.r003

Decision Letter 1

Vasantha kumari Neela, Armanda Bastos

12 Nov 2021

Dear Dr.Tetsuya Kakita ,

We are pleased to inform you that your manuscript 'Laboratory diagnostic, epidemiological, and clinical characteristics of human leptospirosis in Okinawa Prefecture, Japan, 2003–2020' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Vasantha kumari Neela

Associate Editor

PLOS Neglected Tropical Diseases

Armanda Bastos

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0009993.r004

Acceptance letter

Vasantha kumari Neela, Armanda Bastos

29 Nov 2021

Dear Dr. Kakita,

We are delighted to inform you that your manuscript, "Laboratory diagnostic, epidemiological, and clinical characteristics of human leptospirosis in Okinawa Prefecture, Japan, 2003–2020," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Estimated infection source of leptospirosis patients from September 1988 to October 2003 (N = 81).

    (DOCX)

    S2 Table. Comparisons of age and sex ratio of patients by estimated infection source (N = 245).

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers211022.docx

    Data Availability Statement

    All flaB sequences are available from the DDBJ database (accession numbers LC642635–LC642675). All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES